Hoersholm; September 27th, 2016 – Medical Prognosis Institute A/S (MPI.ST) (Denmark and Phoenix, AZ, USA) today announced that the Chinese Patent Office has notified MPI that it has granted a patent on MPIs Drug Response Predictor – DRP(TM) – technology covering 8 relevant anti-cancer drugs including cisplatin. The patent has previously been granted in USA and Japan.
“We are pleased to see this patent, covering 8 relevant anti-cancer drugs including cisplatin, which has previously been granted in the USA and Japan, now granted in China as well. The DRP is MPIs core technology and China is an interesting market,” said CEO Peter Buhl Jensen.
About MPI’s multiple biomarker called Drug Response Predictor – DRP(TM) and Personalized Response Predictor – PRP(TM)
MPI’s DRP(TM) and PRP(TM) are tools for developing tumor-derived genetic signatures to predict which cancer patients will respond with a high likelihood to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anti-cancer drug. In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) and PRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP(TM) and PRP(TM) are Big Data tools based on messenger RNA.
The DRP(TM) platform i.e. the DRP(TM) and the PRP(TM) tools can be used in all cancer types, and is patented for more than 60 anti-cancer drugs in the US. The DRP(TM) is used in Oncology Venture – a spinout from MPI – for drug development. The PRP(TM) is used by MPI for Personalized Medicine.
About MPI
Medical Prognosis Institute A/S is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI’s exceptional opportunity to personalize cancer treatment – begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI’s DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,100 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.
For further information, please contact:
CEO, Peter Buhl Jensen, Adjunct Professor, MD, PhD Ulla Hald Buhl, IR & Communication
E-mail: [email protected] E-mail: [email protected]
Telephone: +45 21 60 89 22 Telephone +45 21 70 10 49
This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on September 27th 2016.
Certified Advisor: Sedermera Fondkommission, Norra Vallgatan 64, 211 22, Malmö, Sweden
